In a bold move aimed at redrawing the map of digital health, Hims & Hers Health said Thursday it will acquire Australian telehealth firm Eucalyptus in a deal valued at up to $1.15 billion.

The transaction, a sweeping expansion play, signals that Hims & Hers to Acquire Eucalyptus is more than a headline — it’s a calculated leap into new international terrain as the U.S.-based telehealth platform seeks to scale its personalized care model beyond its home market.

A Strategic Bridge Across Continents

If completed, the acquisition would hand Hims & Hers a ready-made footprint in Australia and Japan. It would also deepen the company’s reach in the United Kingdom, Germany and Canada through partnerships with established regional operators.

Like a chess player advancing multiple pieces at once, Hims & Hers is positioning itself to serve patients across continents, building out a global infrastructure for customized healthcare delivery.

Eucalyptus operates several consumer-facing brands worldwide, including weight-loss platform Juniper and men’s telehealth service Pilot. According to Hims & Hers, the company has served more than 775,000 customers globally — a sizable base that could accelerate cross-border growth.

Legal Clouds Loom as Expansion Continues

The expansion effort comes at a turbulent time. Hims & Hers is currently locked in litigation with Danish drugmaker Novo Nordisk, following regulatory scrutiny tied to weight-loss treatments.

The dispute arose after a crackdown from the U.S. Food and Drug Administration forced Hims & Hers to abruptly withdraw its newly launched $49 copy of Novo Nordisk’s blockbuster weight-loss drug, Wegovy. The legal fight adds a layer of complexity as the company simultaneously presses forward with international growth.

Deal Terms and Timeline

The acquisition is expected to close in the middle of calendar year 2026, subject to customary conditions.

Hims & Hers said approximately $240 million of the purchase price will be paid in cash at closing, with the remainder structured in accordance with the transaction’s terms, bringing the total deal value to as much as $1.15 billion.

As digital health platforms race to capture global demand, the acquisition underscores an industry in motion — where borders blur, patients click instead of queue, and telehealth giants move swiftly to claim new ground.